| Source: |
| Type: |
| Drug dosage vs efficacy, and actual dosage number of research papers. |
| 2816- | CUR, | NEUROPROTECTIVE EFFECTS OF CURCUMIN |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 1609- | CUR, | EA, | Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells |
| - | in-vitro, | Cerv, | NA |
| 1616- | CUR, | EA, | Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid |
| - | in-vitro, | Nor, | NA |
| 1980- | CUR, | Rad, | Thioredoxin reductase-1 (TxnRd1) mediates curcumin-induced radiosensitization of squamous carcinoma cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Laryn, | FaDu |
| 1977- | CUR, | Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 |
| 1809- | CUR, | Oxy, | Long-term stabilisation of myeloma with curcumin |
| - | Case Report, | Melanoma, | NA |
| 3794- | CUR, | Curcumin hybrid molecules for the treatment of Alzheimer's disease: Structure and pharmacological activities |
| - | Review, | AD, | NA |
| 3574- | CUR, | The effect of curcumin (turmeric) on Alzheimer's disease: An overview |
| - | Review, | AD, | NA |
| 3590- | CUR, | The Holy Grail of Curcumin and its Efficacy in Various Diseases: Is Bioavailability Truly a Big Concern? |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| - | Analysis, | GBM, | NA |
| 7445- | CYN, | Cynaropicrin Shows Antitumor Progression Potential in Colorectal Cancer Through Mediation of the LIFR/STATs Axis |
| - | vitro+vivo, | CRC, | RKO | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | DLD1 |
| 7444- | CYN, | The Sesquiterpene Lactone Cynaropicrin Manifests Strong Cytotoxicity in Glioblastoma Cells U-87 MG by Induction of Oxidative Stress |
| - | in-vitro, | GBM, | U87MG |
| 6255- | Cyste, | Cysteamine Suppresses Cancer Cell Invasion and Migration in Glioblastoma through Inhibition of Matrix Metalloproteinase Activity |
| - | in-vitro, | GBM, | NA |
| 6592- | DAS, | Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial |
| - | Trial, | CML, | NA |
| 6591- | DAS, | Dasatinib in solid tumors |
| - | Review, | Var, | NA |
| 6590- | DAS, | Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 6683- | DCA, | Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts |
| - | Review, | Var, | NA |
| 6681- | DCA, | Dichloroacetate (DCA) in Cancer Care |
| - | Review, | Var, | NA |
| 6679- | DCA, | GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial |
| - | Trial, | Melanoma, | NA |
| 1879- | DCA, | Long-term stabilization of metastatic melanoma with sodium dichloroacetate |
| - | Case Report, | Melanoma, | NA |
| 1877- | DCA, | Non-Hodgkin′s Lymphoma Reversal with Dichloroacetate |
| - | Case Report, | lymphoma, | NA |
| 1873- | DCA, | Dual-targeting of aberrant glucose metabolism in glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 1868- | DCA, | MET, | Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy |
| - | Case Report, | CRC, | NA |
| 1864- | DCA, | MET, | Dichloroacetate Enhances Apoptotic Cell Death via Oxidative Damage and Attenuates Lactate Production in Metformin-Treated Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
| 6702- | DFC, | Diclofenac |
| - | Review, | Nor, | NA |
| 6695- | DFC, | Inhibition of lactate dehydrogenase A by diclofenac sodium induces apoptosis in HeLa cells through activation of AMPK |
| - | in-vitro, | Cerv, | HeLa |
| 6694- | DFC, | Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent |
| - | Review, | Var, | NA |
| 6689- | DFC, | Diclofenac-Induced Apoptosis in the Neuroblastoma Cell Line SH-SY5Y: Possible Involvement of the Mitochondrial Superoxide Dismutase |
| - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 6745- | DHA, | Omega-3 fatty acid DHA induces ferroptosis in colorectal cancer patient-derived organoids and drug-tolerant cells |
| - | in-vitro, | CRC, | HT29 |
| 6753- | DHA, | Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting (DHA-WIN) |
| - | Trial, | BC, | NA |
| 6758- | DHA, | Chemo, | Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial |
| - | Trial, | BC, | NA |
| 6762- | DHA, | EPA, | Long-Chain Omega-3 Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid and Blood Pressure: A Meta-Analysis of Randomized Controlled Trials |
| - | Review, | Nor, | NA |
| 2152- | dietFMD, | Prolonged Nightly Fasting and Breast Cancer Prognosis |
| - | Analysis, | BC, | NA |
| 1853- | dietFMD, | Impact of Fasting on Patients With Cancer: An Integrative Review |
| - | Review, | Var, | NA |
| 1863- | dietFMD, | Chemo, | Effect of fasting on cancer: A narrative review of scientific evidence |
| - | Review, | Var, | NA |
| 1841- | dietFMD, | Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer |
| - | Trial, | Var, | NA |
| 1810- | dietKeto, | Oxy, | The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer |
| - | in-vivo, | Var, | NA |
| 2165- | dietP, | SFN, | Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects—results from the POUDER pilot study |
| - | Trial, | PC, | NA |
| 5065- | dietSTF, | dietFMD, | Nutrition, GH/IGF-I Signaling, and Cancer |
| - | Review, | Var, | NA |
| 5069- | dietSTF, | The Role of Intermittent Fasting in the Activation of Autophagy Processes in the Context of Cancer Diseases |
| - | Review, | Var, | NA |
| 8857- | DIM, | Induction of G1 and G2/M cell cycle arrests by the dietary compound 3,3'-diindolylmethane in HT-29 human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| - | Trial, | Cerv, | NA |
| 8834- | DIM, | Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial |
| - | Trial, | Cerv, | NA |
| 8826- | DIM, | Single-Dose Pharmacokinetics and Tolerability of Absorption-Enhanced 3, 3′-Diindolylmethane in Healthy Subjects |
| - | Study, | Nor, | NA |
| 8829- | DIM, | Anti-androgenic activity of absorption-enhanced 3, 3’-diindolylmethane in prostatectomy patients |
| - | NA, | Pca, | NA |
| 8830- | DIM, | Tam, | A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen |
| - | Trial, | BC, | NA |
| 8831- | DIM, | 3,3′-Diindolylmethane Exhibits Significant Metabolism after Oral Dosing in Humans |
| - | Human, | Nor, | NA |
| 8832- | DIM, | Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy |
| - | Trial, | Pca, | NA |
| 8833- | DIM, | A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer |
| 8854- | DIM, | Rad, | 3,3′-Diindolylmethane: A Promising Sensitizer of γ-Irradiation |
| - | in-vitro, | BC, | MCF7 |
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1114 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid